NC181
/ NextCure
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
March 06, 2025
NextCure Provides Business Update and Reports Full Year 2024 Financial Results
(GlobeNewswire)
- "Preclinical Non-Oncology Programs Seeking Partnering: Preclinical data for NC181 (ApoE4), a humanized antibody for the treatment of Alzheimer’s disease, has demonstrated amyloid clearance, prevention of amyloid deposition, plaque clearance and reduced neuroinflammation. Preclinical data for NC605 (Siglec-15), a humanized antibody for the treatment of osteogenesis Imperfecta (OI), has demonstrated that NC605 treatment reduced bone loss and enhanced bone quality in mice with OI. Both programs could lead to IND filings within 12 to 18 months if financial support from partners or third parties is secured."
IND • Preclinical • Alzheimer's Disease
August 01, 2024
NextCure Provides Business Update and Reports Second Quarter 2024 Financial Results
(GlobeNewswire)
- "NC181 (APOE4): Seeking partnering or other funding sources with the potential to file an IND mid-2025."
IND • Alzheimer's Disease • CNS Disorders
September 28, 2023
NextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimer’s Disease
(GlobeNewswire)
- "NextCure, Inc...today announced the presentation of preclinical data relating to NC181, a novel humanized antibody targeting ApoE4, for the treatment of Alzheimer’s disease (AD), at the 2nd Annual Neurodegeneration Targets, Drug Discovery for Progressive Central Nervous System Disorders conference....In preclinical AD animal models, NC181 has demonstrated differentiation from amyloid targeted therapies. Key findings from the study include: NC181 binds to amyloid associated ApoE4, resulting in amyloid clearance and prevention of amyloid deposition in mice. Clearance of the ApoE plaques; Normalizes neuroinflammation and restores neuroimmune homeostasis. Improves vasodilation in amyloid laden blood vessels, which results in less vascular toxicity and lower vascular leakage."
Preclinical • Alzheimer's Disease • CNS Disorders • Tauopathies And Synucleinopathies
1 to 3
Of
3
Go to page
1